Goldner imminomedics sales
Cancers Free Full Text PET CT in Patients with Breast Cancer sales, Cancers Free Full Text PET CT in Patients with Breast Cancer sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, A dose escalation expansion study evaluating dose safety and sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, PDF PET CT in Patients with Breast Cancer Treated with Immunotherapy sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, PDF HELENA HER2 Low as a prEdictive factor of response to sales, PDF Trastuzumab Emtansine Plus Non Pegylated Liposomal sales, PDF A dose escalation expansion study evaluating dose safety sales, Title Company DIRECTOR OF IT 15W PHARMACY DIRECTOR OF sales, PDF Abstract GS1 07 Adjuvant palbociclib in HR HER2 early sales, Registered Attendee Companies PharmaMedDevice sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, PDF A dose escalation expansion study evaluating dose safety sales, PDF 685TiPA phase II basket study of MCLA 128 a bispecific sales, PDF Circulating tumor DNA ctDNA to detect neuroendocrine sales, Monoclonal Antibody and Peptide Targeted Radiotherapy of Cancer sales, PDF Real world data on triple negative breast cancer in Latin sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, LBA23MonarcHER A randomized phase II study of abemaciclib plus sales, PDF HELENA HER2 Low as a prEdictive factor of response to sales, PDF HELENA HER2 Low as a prEdictive factor of response to sales, UC San Francisco Previously Published Works sales, Current status of cancer therapy with radiolabeled monoclonal antibody sales, NEFS webapps nefs sample ndc WEB INF database data firms.csv at sales, Christopher Hanyoung Lieu Curriculum Vitae sales, PDF HER2 Low Breast Cancer Molecular Characteristics and Prognosis sales, FEATURED ARTICLE sales, FEATURED ARTICLE sales, Title Company DIRECTOR OF IT 15W PHARMACY DIRECTOR OF sales, PDF Circulating tumor DNA ctDNA to detect neuroendocrine sales, Margetuximab for the treatment of HER2 positive metastatic breast sales, Hepatology sales, PDF HELENA HER2 Low as a prEdictive factor of response to sales, PCT 2004 17 PCT Gazette Weekly Issue No. 17 2004 sales, Margetuximab for the treatment of HER2 positive metastatic breast sales, Hepatology sales, titlebar formnpx.gif sales, Margetuximab for the treatment of HER2 positive metastatic breast sales.
-
Next Day Delivery by DPD
Find out more
Order by 9pm (excludes Public holidays)
$11.99
-
Express Delivery - 48 Hours
Find out more
Order by 9pm (excludes Public holidays)
$9.99
-
Standard Delivery $6.99 Find out more
Delivered within 3 - 7 days (excludes Public holidays).
-
Store Delivery $6.99 Find out more
Delivered to your chosen store within 3-7 days
Spend over $400 (excluding delivery charge) to get a $20 voucher to spend in-store -
International Delivery Find out more
International Delivery is available for this product. The cost and delivery time depend on the country.
You can now return your online order in a few easy steps. Select your preferred tracked returns service. We have print at home, paperless and collection options available.
You have 28 days to return your order from the date it’s delivered. Exclusions apply.
View our full Returns and Exchanges information.